Quantcast

Latest Omeros Corporation Stories

2014-12-15 12:26:37

DALLAS, December 15, 2014 /PRNewswire/ -- ReportsnReports.com adds Ocular Disorders: Rising Therapeutics, Technologies, and Devices 2014 market research report that covers

2014-11-19 08:27:47

- Data Bode Well for Success of Ongoing Phase 2 Trial in Thrombotic Microangiopathies - SEATTLE, Nov.

2014-11-10 16:31:48

-- Omidria(TM) U.S. Commercial Launch Planned for Early 2015 -- SEATTLE, Nov.

2014-10-30 08:35:10

-- Unique Billing Code Allows Separate Payment for Omidria -- SEATTLE, Oct.

2014-10-21 08:33:06

-- Enrollment in Huntington's Trial Suspended Pending Further Assessment of Preclinical Data -- SEATTLE, Oct.

2014-08-11 16:28:03

-- FDA Approval of Omidria(TM) Received on May 30, 2014 - SEATTLE, Aug.

2014-06-02 08:29:17

-- Omeros to Host Conference Call Today at 4:30 p.m. ET -- SEATTLE, June 2, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the U.S.

2014-05-12 16:29:07

-- Secures Additional $50.4 Million in Cash in 1Q 2014 -- SEATTLE, May 12, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering,


Word of the Day
edulcoration
  • The act of sweetening by admixture of some saccharine substance.
The word 'edulcoration' comes from a Latin word meaning 'making sweet'.